Epstein‒Barr virus-associated cellular immunotherapy

Cytotherapy. 2023 Sep;25(9):903-912. doi: 10.1016/j.jcyt.2023.04.003. Epub 2023 May 6.

Abstract

Epstein‒Barr virus (EBV) is a human herpes virus that is saliva-transmissible and universally asymptomatic. It has been confirmed that more than 90% of the population is latently infected with EBV for life. EBV can cause a variety of related cancers, such as nasopharyngeal carcinoma, diffuse large B-cell lymphoma, and Burkitt lymphoma. Currently, many clinical studies have demonstrated that EBV-specific cytotoxic T lymphocytes and other cell therapies can be safely and effectively transfused to prevent and treat some diseases caused by EBV. This review will mainly focus on discussing EBV-specific cytotoxic T lymphocytes and will touch on therapeutic EBV vaccines and chimeric antigen receptor T-cell therapy briefly.

Keywords: Epstein‒Barr virus; cellular Immunotherapy; cytotoxic T Lymphocyte; therapeutic method.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Burkitt Lymphoma* / therapy
  • Epstein-Barr Virus Infections*
  • Herpesvirus 4, Human
  • Humans
  • Immunotherapy
  • T-Lymphocytes, Cytotoxic